Bright Minds Biosciences Inc. (DRUG.CN)
| Previous Close | 1.6500 |
| Open | 0.0000 |
| Bid | 1.3500 x N/A |
| Ask | 3.3000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 750 |
| Market Cap | 7.365M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is excited to announce a fully management-subscribed, non-brokered private placement. This placement involves up to 661,765 units of the Company (the "Units") at a price of $1.36 per Unit, aiming for aggregate gross proceeds of up to $900,000 (the "Offering").
GlobeNewswireBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study -- Proof of Mechanism and target engagement in the brain was established using blood biomarkers and qEEG -- In qEEG, BMB-101 demonstrated robust increase in central delta power and robust
- GlobeNewswire
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study -- BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- Brig
